Q2 EPS Forecast for Delcath Systems Reduced by Analyst

Delcath Systems, Inc. (NASDAQ:DCTH – Free Report) – Analysts at HC Wainwright dropped their Q2 2027 earnings per share (EPS) estimates for Delcath Systems in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.11 for the quarter, down from their prior estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Delcath Systems’ FY2028 earnings at $0.68 EPS, FY2029 earnings at $1.08 EPS and FY2030 earnings at $1.61 EPS.

A number of other equities analysts have also issued reports on DCTH. Weiss Ratings lowered shares of Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Zacks Research cut shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 6th. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, BTIG Research raised their price target on shares of Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a report on Monday. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $29.33.

View Our Latest Report on DCTH

Delcath Systems Stock Down 1.8%

Shares of NASDAQ:DCTH opened at $21.38 on Wednesday. The firm has a market cap of $743.81 million, a P/E ratio of 133.62 and a beta of 0.62. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $22.51. The company’s 50-day moving average price is $15.80 and its two-hundred day moving average price is $12.65.

Delcath Systems (NASDAQ:DCTH – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.26. The business had revenue of $35.10 million during the quarter, compared to analysts’ expectations of $25.99 million. Delcath Systems had a return on equity of 5.56% and a net margin of 6.05%.

Hedge Funds Weigh In On Delcath Systems

Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its holdings in Delcath Systems by 31.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,069 shares during the last quarter. Alps Advisors Inc. lifted its position in Delcath Systems by 30.3% during the 3rd quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock valued at $729,000 after purchasing an additional 10,600 shares during the period. Kopp Family Office LLC bought a new position in shares of Delcath Systems in the 3rd quarter valued at about $450,000. Integrated Wealth Concepts LLC bought a new position in shares of Delcath Systems in the 2nd quarter valued at about $48,000. Finally, IFP Advisors Inc bought a new position in shares of Delcath Systems in the 2nd quarter valued at about $52,000. Institutional investors own 61.12% of the company’s stock.

Key Delcath Systems News

These are some of the DCTH news items that stood out recently:

  • Positive Sentiment: HC Wainwright reiterated its Buy rating and $36 price target while lifting its FY2026 EPS estimate to $0.13 from a projected loss of $0.17 and its FY2027 estimate to $0.33 from $0.12. The higher forecasts imply improved expectations for profitability. Article: HC Wainwright earnings estimate revisions
  • Positive Sentiment: A Zacks report says the analyst consensus price target suggests 27.7% upside and notes that upward earnings-estimate revisions could support the stock. It cautions, however, that price targets alone have limited predictive value. Article: Wall Street analysts see potential upside
  • Neutral Sentiment: HC Wainwright trimmed its Q2 2027 EPS forecast slightly, to $0.11 from $0.12, while raising its estimates for FY2028–FY2030. The adjustments point to a mixed but generally improving longer-term outlook. Article: HC Wainwright future earnings estimates

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

Recommended Stories

Earnings History and Estimates for Delcath Systems (NASDAQ:DCTH)

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.